June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
Inflammatory cytokine analysis of ocular fluids from a primate model of chronic vascular leakage and neovascularization
Author Affiliations & Notes
  • Chintan Patel
    RxGen, New Haven, Connecticut, United States
  • Donnicia James
    RxGen, New Haven, Connecticut, United States
  • Wenzheng Hu
    RxGen, New Haven, Connecticut, United States
  • Robin J Goody
    RxGen, New Haven, Connecticut, United States
  • Rahel Zulliger
    Roche, Basel, Switzerland
  • Gabriella Widmer
    Roche, Basel, Switzerland
  • Peter D Westenskow
    Roche, Basel, Switzerland
  • Matthew S Lawrence
    RxGen, New Haven, Connecticut, United States
  • Footnotes
    Commercial Relationships   Chintan Patel, None; Donnicia James, None; Wenzheng Hu, None; Robin Goody, None; Rahel Zulliger, None; Gabriella Widmer, None; Peter Westenskow, None; Matthew Lawrence, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 5395. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chintan Patel, Donnicia James, Wenzheng Hu, Robin J Goody, Rahel Zulliger, Gabriella Widmer, Peter D Westenskow, Matthew S Lawrence; Inflammatory cytokine analysis of ocular fluids from a primate model of chronic vascular leakage and neovascularization. Invest. Ophthalmol. Vis. Sci. 2020;61(7):5395.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The development of wet age-related macular degeneration (AMD), involving vascular leakage and neovascularization (NV), is mediated by various inflammatory and angiogenic cytokines. VEGF, IL-8, FGF, angiopoietins (Ang) and their interplay have been broadly implicated in wet AMD, diabetic retinopathy and retinal vein occlusion. Here we present analysis of pro-inflammatory and pro-angiogenic cytokines perturbed in a nonhuman primate (NHP) model of chronic retinal vascular leakage and NV induced by the gliotoxin DL-2-aminoadipic acid (DLAAA).

Methods : African green monkey aqueous and vitreous humor were sampled from control and DLAAA-treated eyes at baseline and weeks 2, 6, 8, 10 and 12 for cytokine analysis. Samples were analyzed using R&D Systems kit (LXSAHM; Minneapolis, USA) or with beads from Luminex Corp (Austin, USA) coated with antibodies in-house. They were diluted 1:5 with assay buffer from the kit or in-house assay buffer. Analysis of beads was performed on a Flexmap 3D system and data analyzed with a LiquiChip Analyzer (Luminex Corp). Eyes were imaged preceding sample collection at each time point.

Results : DLAAA treatment triggered morphological changes in the retina and perturbed a number of cytokines in both aqueous and vitreous humor during early (weeks 2, 6) and late phases (weeks 8, 10, 12) compared to their respective controls. Cytokines significantly elevated during both the early phase and late phase included Ang1, Angptl-4 and gp130 in the aqueous, and Ang1, MCP-1, Angptl-4, gp130, IL-6ra and CRP in the vitreous. Cytokines remaining elevated during early phase but declining during late phase included Ang2, IL-6, MCP-1, S100B, IL-6ra and CRP in the aqueous, and Ang2, IL-6 and S100B in the vitreous. Additionally, aqueous levels of FGF, VEGF and Ang2 were higher at weeks 2, 6 and 8, and the vitreous levels of VEGF and Ang2 were elevated early and later at weeks 8 and 10. These findings highlight a role of interplay of these cytokines in ocular fluids in advancing and stabilizing the DLAAA pathology.

Conclusions : Perturbations in VEGF and Ang2 levels within ocular fluids in response to DLAAA mimic clinical findings in patients with chronic retinal vascular disease. These cytokines response align with pathological changes and together illustrate the utility of the NHP DLAAA model for evaluating novel agents for treatment of chronic retinal vascular diseases.

This is a 2020 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.